From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Health-Related Quality of Life Data Collected in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Clinical Trials

Last Updated: Tuesday, May 17, 2022

Chimeric antigen receptor T-cell (CAR-T) therapy represents a novel approach to cancer treatment, particularly advanced cancer. Much of the current evidence for the effectiveness of these therapies is associated with considerable uncertainty. The objective of this research was to investigate the frequency with which HRQoL data is collected in currently registered clinical trials investigating CAR-T cancer treatment.

Journal of Cancer Policy
Advertisement
News & Literature Highlights

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Hematology

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

Hematology

Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Advertisement
Case Studies

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts

Fast Facts #12: BCMA Targets

Advertisement
Quizzes
Test your knowledge of atypical manifestation of neurotoxicity following CAR T-cell therapy
Test your knowledge of CAR T-cell therapy
Test your knowledge of CAR T-cell infusion in an outpatient setting